NCT01082302已完成4 期
An Open-Label, Single-Center Phase I (Phase IV/ USA) Study to Assess the Pharmacokinetic Profile of Topically Applied Veregen® 15% in Patients With External Genital and Perianal Warts Compared With Oral Intake of a Green Tea Beverage
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- MediGene
- 入组人数
- 43
- 试验地点
- 1
- 主要终点
- Pharmacokinetic profile of green tea catechins
研究概览
简要总结
This open, monocentric study is designed to investigate plasma concentrations of certain catechins after topical application of Veregen 15% ointment to genital or perianal warts in comparison to catechin plasma concentrations after oral intake of a defined dose of green tea beverage. The study is intended to demonstrate that topical administration of Veregen 15% induces catechin plasma concentrations lower or equivalent to those that can be reached with normal consumption of green tea.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •For both subject groups (treatment arms 1 + 2):
- •Male and female subjects, 18 years of age or older at the time of enrollment. Subjects will be stratified by gender.
- •Written informed consent.
- •Ability to comply with the requirements of the study.
- •For patients (treatment arm 1, additionally):
- •Clinical diagnosis of external genital and perianal warts which can be located: in men: over the glans penis, foreskin, penis shaft, and scrotum; in women: on the vulva; in both gender: in the inguinal, perineal, and perianal areas.
- •A total wart area of at least 100 mm² and a maximum of 2500 mm².
- •For women of child-bearing potential: negative pregnancy test and willingness to use two effective methods of contraception throughout their study participation is mandatory (oral contraceptives, hormone containing intrauterine device, depot injection, hormone implant, or sterilization (for contraception) plus condom (for prevention of reinfection). For male patients and partners of male patients who are of childbearing potential: use of two methods of effective contraception during the treatment period is mandatory (oral contraceptives, hormone containing intrauterine device, depot injection, hormone implant, or sterilization (for contraception) plus condom (for prevention of reinfection).
排除标准
- •For both subject groups (treatment arms 1 + 2):
- •Participation in an investigational trial within 30 days prior to enrollment and for the whole study duration.
- •Any current uncontrolled infection.
- •Current known acute or chronic infection with Hepatitis virus B or C.
- •Known Human immunodeficiency virus infection.
- •Subjects with known history of chronic (diabetes, hypertension, gastritis, etc.) or consuming diseases (cancer, multiple sclerosis, etc.), chronic inflammation, or liver or renal insufficiency.
- •Any chronic or acute condition including the skin, susceptible, in the opinion of the investigator, of interfering with the evaluation of the drug effect.
- •Laboratory data above the upper normal range.
- •Systemic intake of virostatics within 30 days prior to enrollment and for the whole study duration, with the exception of acyclovir and the related drugs famciclovir and valaciclovir.
- •Systemic intake of immunosuppressive or immuno-modulatory medication or vaccination within 30 days prior to enrollment and for the whole study duration.
- •Organ allograft recipient.
- •Medication intake, including over the counter products and dietary supplements such as iodine, fluoride, or vitamins, which would interfere with study results, except paracetamol and oral contraceptives, within one week before and during the study course. Subjects are not allowed to consume green, black or Oolong tea as well as red wine or any other beverages or foods containing green tea extract within three days before each blood sampling visit.
- •For female patients: pregnancy or lactation.
- •Blood transfusion within 30 days prior to enrollment.
- •Subjects who are placed in an institution due to a judicial or official directive.
- •For patients (treatment arm 1, additionally):
- •Previous participation in a trial investigating sinecatechins in the treatment of external genital and perianal warts.
- •Treatment of external genital warts within 30 days prior to enrollment and for the whole study duration.
- •Current infection with Herpes genitalis or history of Herpes genitalis infection within the last 3 months prior to enrollment.
- •Any current and/or recurrent pathologically relevant genital infections other than genital warts.
- •Known allergies against any of the ingredients of the ointment.
研究组 & 干预措施
oral intake of green tea beverage
Active Comparator
Healthy volunteers are asked to drink a defined amount of green tea beverage over 7 days
干预措施: Green Tea Beverage with defined catechin content (Other)
Polyphenon E 15% ointment
Experimental
3 times daily application of Polyphenon E 15% ointment on genital and perianal warts over 7 days
干预措施: Polyphenon E (Veregen) 15% ointment (Drug)
结局指标
主要结局
Pharmacokinetic profile of green tea catechins
时间窗: Day 1/2 and Day 7/8
Cmax, tmax, t1/2, AUC(0-t), and AUC of EGCg, EGC, ECg, and EC
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Clinical Trial of the Study Medicine (Called Fosmanogepix) in Participants With Varying Degrees of Hepatic Function.Hepatic ImpairmentNCT05582187Basilea Pharmaceutica28
已完成
1 期
Plasma Pharmacokinetics and Safety of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Subjects With PresbyopiaEye DiseasesRefractive ErrorsBrimonidine TartrateAceclidineOphthalmic SolutionsPresbyopiaNCT05936489LENZ Therapeutics, Inc30
已完成
1 期
Study to Evaluate the Pharmacokinetics and Metabolism of [14C] CR845 (Difelikefalin) in Patients With End Stage Renal Disease on Hemodialysis and in Healthy SubjectsHemodialysisHealthyNCT03947970Cara Therapeutics, Inc.12
已完成
不适用
Absorption, Metabolism, and Excretion of (-)-[2-14C]Epicatechin in HumansADMENCT01969994The Institutes for Pharmaceutical Discovery, LLC12
已完成
1 期
A Study to Evaluate the Absorption, Metabolism, and Excretion of [14C]BMS-986419 in Healthy Male ParticipantsHealthy VolunteersNCT05847439Bristol-Myers Squibb8